← Back to all substances
A

empagliflozin

224ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients...

Known as: Synjardy
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
9,302
Total in FDA
78%
Serious Reports
44
Fatal Outcomes

Seriousness

Serious
389
Non-Serious
111

Sex Distribution

Male
303
Female
166
Unknown
31

Age Distribution

0-17
2
18-40
25
41-64
225
65-84
177
85+
6
Unknown
65

Outcomes

Recovered/Resolved
470
Recovering/Resolving
102
Not Recovered/Not Resolved
225
Recovered with Sequelae
12
Fatal
44
Unknown
465

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-30646b
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...